Texas Yale Capital Corp. reduced its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 50.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,586 shares of the medical technology company’s stock after selling 53,586 shares during the period. Texas Yale Capital Corp. owned about 0.08% of Hill-Rom worth $5,606,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. bought a new position in shares of Hill-Rom during the 1st quarter valued at approximately $30,000. Sageworth Trust Co bought a new position in shares of Hill-Rom during the 1st quarter valued at approximately $32,000. Financial Gravity Wealth Inc. bought a new position in shares of Hill-Rom during the 1st quarter valued at approximately $53,000. Osborn Williams & Donohoe LLC bought a new position in shares of Hill-Rom during the 1st quarter valued at approximately $53,000. Finally, Bay Harbor Wealth Management LLC grew its position in shares of Hill-Rom by 78.9% during the 2nd quarter. Bay Harbor Wealth Management LLC now owns 535 shares of the medical technology company’s stock valued at $56,000 after acquiring an additional 236 shares during the period. 81.40% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently weighed in on HRC shares. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday. Barclays increased their target price on shares of Hill-Rom from $103.00 to $108.00 and gave the company an “equal weight” rating in a research report on Monday, April 15th. Finally, Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 target price for the company in a research report on Thursday, June 6th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Hill-Rom currently has a consensus rating of “Buy” and an average target price of $107.50.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, August 2nd. The medical technology company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.21 by $0.02. The company had revenue of $726.80 million for the quarter, compared to analysts’ expectations of $718.08 million. Hill-Rom had a net margin of 7.93% and a return on equity of 21.30%. Hill-Rom’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 EPS. Equities research analysts forecast that Hill-Rom Holdings, Inc. will post 5.04 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Friday, September 20th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend is Thursday, September 19th. Hill-Rom’s payout ratio is currently 17.68%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: What is a stock portfolio tracker?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.